Neovasc, Inc.(“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) was featured in three presentations across Germany this month.
The presentations included:
- At the 20th Cardiology Symposium, held January 11, 2020 in Berlin, Prof. Tommaso Gori, Uniklinik Mainz, gave a presentation during the session “Follow up and Ausblick”, titled, “When there is no option to treat angina pectoris anymore: The Reducer”
- At the 20th Cardiology Symposium – Cardiac Surgery Update held January 17, 2020 in Dortmund, Dr. Joachim Weber-Albers, St.-Johannes-Hospital Dortmund, presented and moderated a “live in the box case” during the Coronary Artery Disease session.
- At a workshop held January 22, 2020 in Landshut by the Krankenhaus Achdorf, in cooperation with Berlin-Chemie and Neovasc, Dr. Stylianos Pyxaras presented the Reducer as a new treatment option for chronic angina.
